Back to Search Start Over

EP08.01-098 Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation.

Authors :
Mo, x.
Dong, L.
Patel, S.
DiCostanzo, D.
Alahmadi, A.
Kaufman, J.
Memmott, R.
He, K.
Bertino, E.
Presley, C.
Shields, P.
Otterson, G.
Carbone, D.P.
Welliver, M.X.
Owen, D.H.
Source :
Journal of Thoracic Oncology; 2022 Supplement, Vol. 17 Issue 9, pS389-S389, 1p
Publication Year :
2022

Details

Language :
English
ISSN :
15560864
Volume :
17
Issue :
9
Database :
Complementary Index
Journal :
Journal of Thoracic Oncology
Publication Type :
Academic Journal
Accession number :
159037916
Full Text :
https://doi.org/10.1016/j.jtho.2022.07.670